Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093763 | 0.83 | KMT2A (0.68) | KMT2ACES1MEN1POLBALDH1A1 | |
| SCHEMBL18596893 | 0.83 | KMT2A (0.52) | KMT2AEPHX2CES1MEN1POLB | |
| SCHEMBL5946857 | 0.79 | KMT2A (0.55) | KMT2AEPHX2MEN1POLBHSD11B1 | |
| SCHEMBL5946952 | 0.79 | KMT2A (0.55) | KMT2AEPHX2MEN1POLBHSD11B1 | |
| SCHEMBL6672054 | 0.77 | KMT2A (0.50) | KMT2AEPHX2CES1MEN1POLB | |
| SCHEMBL26706250 | 0.76 | KMT2A (0.70) | KMT2AEPHX2MEN1POLBCA1 | |
| SCHEMBL6675799 | 0.76 | KMT2A (0.49) | KMT2AEPHX2CES1MEN1POLB | |
| SCHEMBL4724436 | 0.76 | KMT2A (0.75) | KMT2AEPHX2MEN1POLBCA1 | |
| SCHEMBL1877246 | 0.76 | KMT2A (0.80) | KMT2AEPHX2MEN1POLBCA1 | |
| SCHEMBL30583807 | 0.75 | NPC1 (0.62) | KMT2AEPHX2CES1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586899-B2 | Synthetic process for aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2017-03-07 | — | — | US | disclosed |
| US-20150336887-A1 | SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS | CORREVIO CANADA CORP. (CA) | 2015-11-26 | — | — | US | disclosed |
| US-9115081-B2 | Synthetic process for aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2015-08-25 | — | — | US | disclosed |
| US-8692002-B2 | Synthetic process for aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2014-04-08 | — | — | US | disclosed |
| US-20130102791-A1 | SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2013-04-25 | — | — | US | disclosed |
| US-7820862-B2 | Ligand, method for producing the same, and catalyst using the ligand | THE UNIVERSITY OF TOKYO (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7799934-B2 | Intermediates (synthons) in the synthesis of pharmaceuticals such as oseltamivir and other products; treating the arizidine with the nucleophile in the presence of a biaryl phosphoric acid catalyst | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090030212-A1 | Enantioselective ring-opening of aziridines | UNIVERSITY OF SOUTH FLORIDA OF TAMPA | 2009-01-29 | — | — | US | disclosed |
| US-20090023579-A1 | Ligand, Method for Producing the Same, and Catalyst Using the Ligand | THE UNIVERSITY OF TOKYO (JP) | 2009-01-22 | — | — | US | disclosed |
| WO-2009005775-A2 | ENANTIOSELECTIVE RING-OPENING OF AZIRIDINES | UNIVERSITY OF SOUTH FLORIDA (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023579-A1 | Ligand, Method for Producing the Same, and Catalyst Using the Ligand | CHRM1, CHRM2, B3GNT2 | KMT2A 1537/4885EPHX2 1217/4885CES1 340/4885 |
| US-20130102791-A1 | SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS | DDC, PAICS, CYP4F2 | KMT2A 2038/4885EPHX2 271/4885CES1 628/4885 |
| US-20150336887-A1 | SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS | DDC, PAICS, CYP4F2 | KMT2A 2038/4885EPHX2 271/4885CES1 628/4885 |
| US-20090030212-A1 | Enantioselective ring-opening of aziridines | AZI2, ITPA, ADORA2A | KMT2A 2717/4885EPHX2 183/4885CES1 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.